Although Venezuelan equine encephalitis to investigate the effectiveness of an irradiated (VEE) is spread from mammal to mammal or bird VEE vaccine against challenge via the respiratory to mammal primarily by the bite of an infected route. This report presents data on the responses mosquito, infections have been reported (10) to of guinea pigs vaccinated with an irradiated VEE occur via the respiratory tract in humans and by vaccine to aerosol challenge with VEE virus, contact in horses (9). The hazard of aerosols to laboratory workers who perform studies with
MATERIALS AND METHODS infectious viruses is well documented (16). Pro
^^ yEE vacdne Jhree ^ rf ^^ tection of the laboratory worker by immuniza-vaccine were prepared from suspensions of VEE virus tion with effective vaccines is desirable for in-^^ in human diploid ^n monolayers (WI-38) as vestigations with hazardous microbes. Although described previously (15). Seed virus used for prepa Formalin killed VEE vaccine and a live attenu-aration of vaccines had been passaged 14 times in ated vaccine have been tested in man, the former chick embryos and once in WI-38 cell monolayers. has been found to be ineffective for prevention of Vaccines were prepared from the culture fluids of infection (11) and the latter is associated with WI38 monolayers infected with the seed virus and side reactions in approximately 20% of the vac-* ere .inactivated by exposure to 8 X 10V of «Co. cinees (P. J. Kadull, personal commnnication). Vaccine lots 59/2a59/2b and 59/2d had pre.nact.va-"
A i -' },. n \ _ J lL tion titers of 9.1, 9.3, and 8.9 mouse intraperitoneal Recently one of us (MR.) reported on the 5 0% lethal doses (MIPLD.o) per ml, respectively, development of nonviable VEE vaccines by immunization of guinea pigs. The antigen extincexposure of virus suspensions to gamma radia-t ion test of Cole and McKinney (2) was used to assay tions (15). These vaccines have been shown to the potencies of the vaccines. Guinea pigs (250 to stimulate high levels of protection in vaccinated 350 g) were divided into groups and vaccinated ip guinea pigs and mice against intraperitoneal with 0.2-ml amounts of graded dilutions of vaccine at (ip) challenge with the virulent Trinidad donkey intervals of 1 week for a total of three injections, brain strain of VEE virus (6). It was of interest Dilutions were made in beef heart infusion broth.
Control groups consisted of (i) animals that did not receive vaccinations and (ii) animals that were vaccinated with irradiated tissue culture medium from virus-free monlayers.
Calculation of 50% effective dose. The potency of the vaccine is expressed as the 50% effective dose (EDso), the quantity of undiluted vaccine inoculated per dose that protected 50% of the test animals. The dose that protects 50% of the test animals was calculated by the method of Reed and Muench (13) . EDso values were calculated for aerosol and ip challenge. Thirty-two to 40 animals per group were tested by aerosol and 15 animals per group were tested by ip challenge: ED» 0 -volume of vaccine inoculated per dose (miUUiter) /dilution of vaccine protecting 50% of test animals.
Aerosol challenge. Twenty-three to 24 days postvaccination, animals were challenged with the Trinidad donkey brain strain of VEE virus. Challenge doses are listed in the text for individual experiments.
Aerosolization. AerosoL of VEE virus were produced in a 115,000-liter static aerosol chamber (17; F. E. Ray, Abstr. 136th Meet. Amer. Chem. Soc., p. 27, 1959) employing an atomizer test fixture disseminating device (reference 8, p. 287). The air in the chamber was preconditioned to 75 F (24 C) and 80% RH. Desired aerosol concentrations, and thus guinea pig inhaled doses, were achieved by adjusting the amount of virus preparation disseminated and by diluting the aerosol with clean air adjusted to chamber conditions. Aerosol sampling. Samples of aerosols were collected in AGI 30 impingers fitted with preimpingers (3, 17) and operated for 1 min at a collection rate of 12.5 liters/min. Impingement fluid (20 ml) was Sorensens buffer with egg yolk and Antifoam A [0.025% KHjPO«., 0.267% Na 2 HP0 4 ., distilled water; autoclaved at 15 psi for 15 min and then 0.1% Antifoam A (Dow-Corning Corp., Midland, Mich.) and yolk from 7-day-old embryonated chicken eggs at a ratio of one yolk to four buffer added]. Samples of aerosol were taken at the beginning and end of animal exposure periods to determine infectious units of VEE virus per liter of aerosol. This was achieved by diluting impingement fluid to appropriate dilutions in Heart Infusion Broth (Difco) and titrating intracerebrally in 10-to 14-g Swiss-Webster albino mice of mixed sexes to obtain 50% lethal dose (LD») values (13). Inhaled doses were calculated on the basis of aerosol concentrations, durations of exposures, and the guinea pig respiratory volume (5; reference 8, p. 295, 307). AGI 30 aerosol samplers collect droplet nuclei of about 5 ^m or less in diameter and thus provide an estimate of that fraction of the aerosol inhaled by guinea pigs in the size range effective for initiating respiratory infection (I, 4, 7, 12) . At the time of aerosol exposure, about 40 to 60% of the aerosol was composed of droplets 5 /im or less in diameter.
Aerosol exposure. Control animals and randomly selected guinea pigs from groups consisting of various vaccination levels were placed in perforated containers that were then suspended in the midst of the aerosol. Animals, therefore, were thus relatively unrestrained while being whole-body-exposed; this should have minimized or negated any effect on the normal breathing pattern (reference 8, p. 300).
Serological assay. Ten per cent or more of the animals were bled intracardially before vaccination, 21 days postvaccination, and 14 days postchallenge. Serum samples were assayed for hemagglutinatinginhibiting (HI; reference 14) and serum-neutralizing (SN) antibodies as previously described (15). SN indexes are expressed as logio; HI titers are expressed as the reciprocal.
RESULTS
Efficacy of irradiated vaccines against aerosol challenge. The initial experiment was designed to determine the response of immunized animals to various doses of the challenge virus. Guinea pigs received mean inhaled doses of approximately 6.5 X 10 5 , 6 X 10S 1.6 X 10*, and 1.6 X 10 3 MICLD50. These animals had been vaccinated with lot 59/2a. Table 1 shows that this vaccine was highly effective against aerosol challenge and that no significant difference was apparent in the ED 50 values obtained, which ranged from 0.004 to 0.006 ml.
In the next two experiments, animals were vaccinated with lot 59/2b and lot 59/2d and then challenged with respiratory doses of approximately 3 X 10 5 to 7 X 10 5 and 3 X 10 3 to 6 X 10 3 MICLD50 of VEE virus. In the previous experiment, as well as the next two experiments, the vaccinated guinea pigs unexpectedly did not demonstrate graded death responses to the graded aerosol challenge levels. In the interest of clarity, therefore, it was considered appropriate to evaluate their responses pooled over dose levels to demonstrate better the main experimental effects (namely, vaccine efficacy). Table 2 shows that animals vaccinated with undiluted and 10 -1 dilutions of vaccine had high levels of SN and moderate levels of HI antibodies. These animals were also highly resistant to fatal infection with VEE virus. Table 3 shows the results of HI antibody titrations of serum samples obtained in the final 6.0 X 10' 1.6 X 10* 1.6 X 10" -Lot 59 2a. • Lot 59/2d. 6 Reciprocal of highest serum dilution which produced inhibition of hemagglutination.
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experiment before and after challenge. These data are typical of those obtained in the other experiments. Serum samples taken 14 days after aerosol challenge contained higher levels of SN and HI antibodies than prechallenge samples. Titers of HI antibodies were more elevated in animals challenged with higher doses of VEE virus than in those that received low doses. No correlation is apparent between the concentration of vaccine used for immunization and the postchallenge level of antibody response in animals challenged with > 10 s LD W doses. Although there was some increase in HI antibody levels in animals challenged with > 10 3 LDso, the response was not as marked in animals that received vaccine diluted as high as 1:100. In this experiment, although seven of the animals vaccinated with undiluted vaccine did not have significant HI titers (< 1:10) at the time of challenge, none became ill. Table 4 lists the antibody levels of five animals that responded poorly to vaccination. These animals, however, were able to survive challenge and produced high levels of HI and SN antibodies 2 weeks postchallenge. Table 5 shows that the majority of paired serum samples tested showed a fourfold or greater increase in HI titer after challenge. Only 4 of 47 animals failed to have a significant increase in Higher ED M values for VEE vaccines were obtained when the challenge dose was administered by the aerosol route instead of the ip route. This may be assumed to be due to the fact that the guinea pig is less able to resist infection when the virus is administered by the aerosol route. This is supported by the data showing that the majority of the immunized animals became hyperimmune after challenge with aerosol doses as low as 10 3 2 . Previous studies (15) have shown that this did not occur with guinea pigs challenged ip until doses as high as 10 5 * were reached. Stimulation of antibodies by exposure to the higher doses of virus might be attributed to an anamnestic response to the antigenic mass; this is not true with the lower doses. In these animals, it may be assumed that some multiplication of virus particles occurred that stimulated the antibodyproducing apparatus of the animal. However, it is apparent that the infection was quickly contained as symptoms of illness did not occur. Irradiated VEE vaccines were well tolerated by the guinea pigs. No side reactions were apparent in immunized animals which remained afebrile and continued to gain weight throughout the period of immunization.
Data presented indicate that gamma-irradiated VEE vaccines produced in WI-38 cells are safe and very effective for protection of guinea pigs against aerosol challenge. This type of vaccine also might well offer substantial protection to laboratory workers who may be exposed accidently to aerosols or inoculation with virulent VEE virus.
